This brand name is authorized in Brazil, Singapore, South Africa, Tunisia.
The drug HEXABRIX contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
HQ43CN02U9 - IOXAGLATE SODIUM
|
2
|
UNII
75JR975T11 - IOXAGLATE MEGLUMINE
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| P01CB01 | Meglumine antimonate | P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01C Agents against leishmaniasis and trypanosomiasis → P01CB Antimony compounds |
| V08AB03 | Ioxaglic acid | V Various → V08 Contrast media → V08A X-ray contrast media, iodinated → V08AB Watersoluble, nephrotropic, low osmolar X-ray contrast media |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| BR | Câmara de Regulação do Mercado de Medicamentos | 511000401150419, 511000402157417, 511000404151416 |
| SG | Health Sciences Authority | 06033P |
| TN | Direction de la Pharmacie et du Médicament | 5640021B, 5640021C |
| ZA | Health Products Regulatory Authority | P/28/131 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.